

PROSPECT Lung

A non-small cell lung cancer trial

**Do you have operable
non-small cell lung cancer?**

**Join us to help discover
new treatment options.**



The PROSPECT-Lung Trial is a clinical study for patients with early-stage non-small cell lung cancer (NSCLC). The main purpose of the study is to find out if we can lower the chance of your lung cancer coming back or spreading by either receiving therapy before and after surgery, or receiving therapy only after surgery. Treatment typically lasts a few months to one year, followed by several years of regular follow-up visits to monitor your health and check for recurrence.

Why participate?

This research should help us answer the question of whether giving treatment both before and after surgery (perioperative treatment) or just after surgery (adjuvant treatment) leads to better outcomes in patients with operable stage II-III NSCLC. The goal is to find the most effective treatment strategy to improve survival, reduce recurrence, and enhance overall patient outcomes.

You may be eligible to participate in the PROSPECT-Lung trial if you:

- Have been diagnosed with early-stage NSCLC.
- Have NSCLC that your doctor thinks can be treated with surgery.
- Are at least 18 years old.

Learn more:

- **Talk** to your healthcare provider.
- **Contact** the NCI Cancer Information Service toll-free at 1-800-422-6237
- **Go to** ClinicalTrials.gov and search the national clinical trial number: NCT06632327

This trial is being conducted by the Alliance for Clinical Trials in Oncology and the SWOG Cancer Research Network. Alliance and SWOG both are part of a national research network funded by the National Cancer Institute (NCI) through the Clinical Trials Innovation Unit (CTIU).

